Orally administered 6:2 chlorinated polyfluorinated ether sulfonate (f-53b) causes thyroid dysfunction in rats

So Hye Hong; Seung Hee Lee; Jun Young Yang; Jin Hee Lee; Ki Kyung Jung; Ji Hyun Seok; Sung Hee Kim; Ki Taek Nam; Jayoung Jeong; Jong Kwon Lee; Jae Ho Oh

doi:10.3390/toxics8030054

Orally administered 6:2 chlorinated polyfluorinated ether sulfonate (f-53b) causes thyroid dysfunction in rats

So Hye Hong, Seung Hee Lee, Jun Young Yang, Jin Hee Lee, Ki Kyung Jung, Ji Hyun Seok, Sung Hee Kim, Ki Taek Nam, Jayoung Jeong, Jong Kwon Lee, Jae Ho Oh

BioMedical Science Institute

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

The compound 6:2 chlorinated polyfluorinated ether sulfonate (F-53B), a replacement for perfluorooctanesulfonate (PFOS) in the electroplating industry, has been widely detected in numerous environmental matrices, human sera, and organisms. Due to regulations that limit PFOS use, F-53B use is expected to increase. Therefore, in this study, we performed a subchronic oral toxicity study of F-53B in Sprague Dawley (SD) rats. F-53B was administered orally once daily to male and female rats for 28 days at doses of 5, 20, and 100 mg/kg/day. There were no toxicologically significant changes in F-53B-treated rats, except in the thyroid gland. However, F-53B slightly reduced the serum concentrations of thyroid hormones, including triiodothyronine and thyroxine, compared with their concentrations in the vehicle group. F-53B also induced follicular hyperplasia and was associated with increased thyroid hormone biosynthesis-associated protein expression. These results demonstrate that F-53B is a strong regulator of thyroid hormones in SD rats as it disrupts thyroid function. Thus, caution should be exercised in the industrial application of F-53B as an alternative for PFOS.

Original language	English
Article number	54
Pages (from-to)	1-10
Number of pages	10
Journal	Toxics
Volume	8
Issue number	3
DOIs	https://doi.org/10.3390/toxics8030054
Publication status	Published - 2020 Sept

Bibliographical note

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

All Science Journal Classification (ASJC) codes

Toxicology
Chemical Health and Safety
Health, Toxicology and Mutagenesis

Access to Document

10.3390/toxics8030054

Cite this

@article{6bc1b4bd6ba24b569b811fd647f27d79,

title = "Orally administered 6:2 chlorinated polyfluorinated ether sulfonate (f-53b) causes thyroid dysfunction in rats",

abstract = "The compound 6:2 chlorinated polyfluorinated ether sulfonate (F-53B), a replacement for perfluorooctanesulfonate (PFOS) in the electroplating industry, has been widely detected in numerous environmental matrices, human sera, and organisms. Due to regulations that limit PFOS use, F-53B use is expected to increase. Therefore, in this study, we performed a subchronic oral toxicity study of F-53B in Sprague Dawley (SD) rats. F-53B was administered orally once daily to male and female rats for 28 days at doses of 5, 20, and 100 mg/kg/day. There were no toxicologically significant changes in F-53B-treated rats, except in the thyroid gland. However, F-53B slightly reduced the serum concentrations of thyroid hormones, including triiodothyronine and thyroxine, compared with their concentrations in the vehicle group. F-53B also induced follicular hyperplasia and was associated with increased thyroid hormone biosynthesis-associated protein expression. These results demonstrate that F-53B is a strong regulator of thyroid hormones in SD rats as it disrupts thyroid function. Thus, caution should be exercised in the industrial application of F-53B as an alternative for PFOS.",

author = "Hong, {So Hye} and Lee, {Seung Hee} and Yang, {Jun Young} and Lee, {Jin Hee} and Jung, {Ki Kyung} and Seok, {Ji Hyun} and Kim, {Sung Hee} and Nam, {Ki Taek} and Jayoung Jeong and Lee, {Jong Kwon} and Oh, {Jae Ho}",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = sep,

doi = "10.3390/toxics8030054",

language = "English",

volume = "8",

pages = "1--10",

journal = "Toxics",

issn = "2305-6304",

publisher = "MDPI AG",

number = "3",

}

TY - JOUR

T1 - Orally administered 6:2 chlorinated polyfluorinated ether sulfonate (f-53b) causes thyroid dysfunction in rats

AU - Hong, So Hye

AU - Lee, Seung Hee

AU - Yang, Jun Young

AU - Lee, Jin Hee

AU - Jung, Ki Kyung

AU - Seok, Ji Hyun

AU - Kim, Sung Hee

AU - Nam, Ki Taek

AU - Jeong, Jayoung

AU - Lee, Jong Kwon

AU - Oh, Jae Ho

PY - 2020/9

Y1 - 2020/9

N2 - The compound 6:2 chlorinated polyfluorinated ether sulfonate (F-53B), a replacement for perfluorooctanesulfonate (PFOS) in the electroplating industry, has been widely detected in numerous environmental matrices, human sera, and organisms. Due to regulations that limit PFOS use, F-53B use is expected to increase. Therefore, in this study, we performed a subchronic oral toxicity study of F-53B in Sprague Dawley (SD) rats. F-53B was administered orally once daily to male and female rats for 28 days at doses of 5, 20, and 100 mg/kg/day. There were no toxicologically significant changes in F-53B-treated rats, except in the thyroid gland. However, F-53B slightly reduced the serum concentrations of thyroid hormones, including triiodothyronine and thyroxine, compared with their concentrations in the vehicle group. F-53B also induced follicular hyperplasia and was associated with increased thyroid hormone biosynthesis-associated protein expression. These results demonstrate that F-53B is a strong regulator of thyroid hormones in SD rats as it disrupts thyroid function. Thus, caution should be exercised in the industrial application of F-53B as an alternative for PFOS.

AB - The compound 6:2 chlorinated polyfluorinated ether sulfonate (F-53B), a replacement for perfluorooctanesulfonate (PFOS) in the electroplating industry, has been widely detected in numerous environmental matrices, human sera, and organisms. Due to regulations that limit PFOS use, F-53B use is expected to increase. Therefore, in this study, we performed a subchronic oral toxicity study of F-53B in Sprague Dawley (SD) rats. F-53B was administered orally once daily to male and female rats for 28 days at doses of 5, 20, and 100 mg/kg/day. There were no toxicologically significant changes in F-53B-treated rats, except in the thyroid gland. However, F-53B slightly reduced the serum concentrations of thyroid hormones, including triiodothyronine and thyroxine, compared with their concentrations in the vehicle group. F-53B also induced follicular hyperplasia and was associated with increased thyroid hormone biosynthesis-associated protein expression. These results demonstrate that F-53B is a strong regulator of thyroid hormones in SD rats as it disrupts thyroid function. Thus, caution should be exercised in the industrial application of F-53B as an alternative for PFOS.

UR - http://www.scopus.com/inward/record.url?scp=85096211144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096211144&partnerID=8YFLogxK

U2 - 10.3390/toxics8030054

DO - 10.3390/toxics8030054

M3 - Article

AN - SCOPUS:85096211144

SN - 2305-6304

VL - 8

SP - 1

EP - 10

JO - Toxics

JF - Toxics

IS - 3

M1 - 54

ER -

Orally administered 6:2 chlorinated polyfluorinated ether sulfonate (f-53b) causes thyroid dysfunction in rats

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this